IBI322

BIOLOGICAL3 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Advanced MalignanciesHematologic MalignancyMyeloid Tumor

Phase 1

Safety and Efficacy of IBI322 in Chinese Subjects With Advanced Malignant Tumors

CompletedNCT04328831

Innovent Biologics (Suzhou) Co. Ltd.Advanced Malignancies

Start: 2020-07-31End: 2023-08-28Updated: 2023-10-10

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy

CompletedNCT04795128

Innovent Biologics (Suzhou) Co. Ltd.Hematologic Malignancy

Start: 2021-05-07End: 2023-08-15Updated: 2024-11-06

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

TerminatedNCT05148442

Innovent Biologics (Suzhou) Co. Ltd.Myeloid Tumor

Start: 2021-12-28End: 2023-08-29Updated: 2023-09-08

Related Papers

S216: CD47/PD-L1 BISPECIFIC ANTIBODY (IBI322) IN ANTI-PD-1 OR PD-L1 TREATMENT-RESISTANT CLASSICAL HODGKIN LYMPHOMA: A PHASE I STUDY

HemaSphere2023-08-018 citations

Abstract CT513: Phase I study of IBI322 (anti-CD47/PD-L1 bispecific antibody) monotherapy therapy in patients with advanced solid tumors in China

Cancer Research2022-06-1516 citations